Celcuity to Present at Guggenheim Emerging Outlook: Biotech Summit 2026

miércoles, 4 de febrero de 2026, 11:18 am ET1 min de lectura
CELC--

Celcuity, a clinical-stage biotechnology company, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026. Brian Sullivan, CEO and Co-founder, is scheduled for a fireside chat on Feb. 11. The company is developing targeted therapies for oncology and is currently enrolling patients in Phase 3 clinical trials for its lead therapeutic candidate, gedatolisib.

Celcuity to Present at Guggenheim Emerging Outlook: Biotech Summit 2026

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios